Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mycosis Fungoides 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Flow Cytometry 4Therapeutics 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3liposomal amphotericin B 2Radiotherapy 2Ondansetron 2Itraconazole 2Immunoenzyme Techniques 2Dexamethasone 2Cyclophosphamide 2Caspofungin 2Calcium Dobesilate 2Aprepitant 2Amplified Fragment Length Polymorphism Analysis 2trastuzumab biosimilar HLX02 1temsirolimus 1talimogene laherparepvec 1sargramostim 1romidepsin 1pembrolizumab 1obinutuzumab 1motexafin gadolinium 1liposomal doxorubicin 1flt3 ligand protein 1entinostat 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mycosis Fungoides × obinutuzumab × Breast × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡